ReviewInternational journal of molecular sciences2024
Lupus Nephritis from Pathogenesis to New Therapies: An Update.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Safety and Efficacy of Obinutuzumab in Treating Lupus Nephritis: A Systematic Review.Immunity, inflammation and disease · 2026Pooled it
- Efficacy and safety of calcineurin inhibitor therapy in lupus nephritis: a systematic review and network meta-analysis.Frontiers in immunology · 2025Pooled it
- Jianpi Zishen Decoction ameliorates renal damage induced by systemic lupus erythematosus through inhibition of the TLR4/MAPK pathway.Pharmaceutical biology · 2026Article
- Urinary Exosomes as Potential Biomarkers for Diagnosis, Disease Activity Assessment, Treatment Monitoring, and Prognosis in Lupus Nephritis.International journal of molecular sciences · 2026Review
- Screening of diagnostic biomarkers for taurine metabolism-related genes in lupus nephritis and analysis of immune infiltration.International urology and nephrology · 2026Article
- Investigation of the association between retinal microcirculation and renal function in children with lupus nephritis.Clinical rheumatology · 2026Article
- [Histopathological findings associated with complete clinical remission in patients with lupus nephritis].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Pharmacogenetics and pharmacokinetics of immunosuppressants: clinical correlations and disease activity control in Egyptian female patients with lupus nephritis.Molecular biology reports · 2026Article
- Elevated Serum Soluble Syndecan-1 Is Associated with Lupus Nephritis Flares: A Cross-Sectional Study.International journal of molecular sciences · 2026Article
- CSL305: A Dual Functional Therapeutic Antibody Targeting Complement C2 and FcRn.International journal of molecular sciences · 2026Article
- Micronutrients in Autoimmune Diseases: Shining a Light on Vitamin D, Cobalamin, Folate, and Iron Metabolism.Nutrients · 2026Review
- Reprogramming M2b Macrophages via GPX1 Activation by Selenium Nanoparticles Attenuates Lupus Nephritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- PHLDB1 and WDFY4 as dual-state biomarkers in SLE pathogenesis and lupus nephritis prediction.BMC immunology · 2026Article
- Annexins and autoantibodies in autoimmune diseases - Insights into SLE, APS and RA: A review.Biomolecules & biomedicine · 2026Review
- Therapeutic Potential ofFood science & nutrition · 2026Article
- C1q CIC in Lupus Nephritis: An Analysis of 883 Patients.International journal of medical sciences · 2026Article
- Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026Review
- Molecular mechanisms in podocytopathies: finding suitable targets for a new era of glomerular gene therapy.Clinical kidney journal · 2026Review
- Cross-tissue integrative transcriptomic and multimodal analyses suggest shared immune signatures linking lupus nephritis and cutaneous lupus erythematosus.Frontiers in immunology · 2026Article
- Hyperoside Attenuates Lupus Nephritis-Associated Mesangial Cell Apoptosis via the P53/XAF1 Pathway: Integrative Bioinformatics and In Vitro Validation.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus Nephritis (LN) still represents one of the most severe complications of Systemic Lupus Erythematosus (SLE) and a major risk factor for morbidity and mortality. However, over the last few years, several studies have paved the way for a deeper understanding of its pathogenetic mechanisms and more targeted treatments. This review aims to provide a comprehensive update on progress on several key aspects in this setting: pathogenetic mechanisms of LN, including new insight into the role of autoantibodies, complement, vitamin D deficiency, and interaction between infiltrating immune cells and kidney resident ones; the evolving role of renal biopsy and biomarkers, which may integrate information from renal histology; newly approved drugs such as voclosporin (VOC) and belimumab (BEL), allowing a more articulate strategy for induction therapy, and other promising phase III-immunosuppressive (IS) agents in the pipeline. Several adjunctive treatments aimed at reducing cardiovascular risk and progression of chronic renal damage, such as antiproteinuric agents, represent an important complement to IS therapy. Furthermore, non-pharmacological measures concerning general lifestyle and diet should also be adopted when managing LN. Integrating these therapeutic areas requires an effort towards a holistic and multidisciplinary approach. At the same time, the availability of an increasingly wider armamentarium may translate into improvements in patient's renal outcomes over the next decades.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.